Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors

Background: Primary central nervous system (CNS) tumors grow in the brain and spinal cord. These tumors are rare, but they are difficult to treat and often fatal. SmartMatch is a new technology that tries to help find the best medicines for the particular tumor by testing how small pieces of surgically removed tumor tissue react to different drugs. The study team wants to see if SmartMatch can complete the analysis and generate a report within 21 days from the time of the surgery. Objective: To better understand CNS tumors so doctors can find better ways to treat them in the future. Eligib

Trial Details

NCT ID

NCT07374692

Phase

NA

Sponsor

National Cancer Institute (NCI)

Status

RECRUITING

Cancer Type

Brain Cancer

Interventions

• Tumor sample collection

Locations (sample)

• Bethesda, Maryland, United States|38.98067,-77.10026

Key Eligibility Criteria

• Participants must have advanced CNS tumors confirmed by a documented pathology report, including:
• recurrent isocitrate dehydrogenase (IDH)-wild-type high-grade glioma
• recurrent IDH-mutant gliomas
• other recurrent CNS tumors

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →